CompletedPhase 2NCT05417126

Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Studying Stargardt disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanoscope Therapeutics Inc.
Principal Investigator
Dr Samarendra Mohanty
Nanoscope Therapeutics Inc.
Intervention
Gene Therapy-vMCO-010(biological)
Enrollment
6 enrolled
Eligibility
16 years · All sexes
Timeline
2022 – 2023

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05417126 on ClinicalTrials.gov

Other trials for Stargardt disease

Additional recruiting or active studies for the same condition.

See all trials for Stargardt disease →

← Back to all trials